BioventixLSE:BVXP 62 EBITDA Margin % is 76.98% as of Dec. 2025, which is 2% below its 10-year median of 78.81. GuruFocus rates LSE:BVXP with a GF Score™ of 62/100 and a GF Value™ of £35.80 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 944 Biotechnology companies, Bioventix ranks better than 97.03% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Bioventix's EBITDA for the
six
months ended in Dec. 2025 was £4.74 Mil. Bioventix's Revenue for the
six
months ended in Dec. 2025 was £6.16 Mil. Therefore, Bioventix's EBITDA margin for the quarter that ended in Dec. 2025 was 76.98%.
Bioventix (LSE:BVXP) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Bioventix EBITDA Margin % Related Terms
Bioventix EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Bioventix's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:BVXP vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Bioventix's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioventix EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bioventix's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Bioventix's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioventix (LSE:BVXP) has a EBITDA Margin % of 76.98% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bioventix and its competitors. This is near median its historical median of 78.81. Over the past decade, Bioventix's EBITDA Margin % has ranged from 75.50 to 80.40. According to the industry distribution chart, Bioventix ranks #28 out of 944 companies in the Biotechnology industry, placing it in the top 3%.
Is Bioventix's EBITDA Margin % too high?
Bioventix's current EBITDA Margin % of 76.98% is near median its 10-year median of 78.81. Over the past 10 years, this metric has ranged from a low of 75.50 to a high of 80.40. Based on the distribution chart, Bioventix ranks #28 out of 944 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Bioventix has a GF Score™ of 62/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bioventix's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bioventix ranks #28 out of 944 companies for EBITDA Margin %. This places Bioventix in the top 3% of its industry — outperforming the majority of peers. Historically, Bioventix's own EBITDA Margin % has ranged from 75.50 to 80.40 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bioventix and its competitors. Bioventix's current EBITDA Margin % is 76.98%, which is near median its own 10-year median of 78.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioventix stock overvalued right now?
Based on GuruFocus' analysis, Bioventix (LSE:BVXP) is currently considered Significantly Undervalued. The stock's GF Value™ is £35.80, compared to a current price of £16.75 — trading 53.2% below its estimated fair value. The current EBITDA Margin % is 76.98%, which is near median its 10-year median of 78.81. Bioventix's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Bioventix (LSE:BVXP), the current EBITDA Margin % is 76.98% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioventix (LSE:BVXP) Overvalued in 2026?
Based on GuruFocus' analysis, Bioventix stock appears to be undervalued.
The current stock price of £16.75 is trading 53.2% below its estimated GF Value™ of £35.80.
GuruFocus considers Bioventix to be Significantly Undervalued.
Key valuation signals for LSE:BVXP:
EBITDA Margin %: 76.98% (near median its 10-year median of 78.81)
GF Value™: £35.80 vs. price of £16.75 (53.2% below fair value)
No single metric tells the full story. See the LSE:BVXP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioventix PLC is a biotechnology company based in the United Kingdom. It specializes in the creation and supply of high-affinity sheep monoclonal antibodies and clinical diagnostics and drug abuse testing. The company's portfolio of products includes drugs that are applicable in the areas of cardiology, fertility, infectious diseases, Thyroid, and vitamin D disorder among others. It earns maximum revenue from European country.
62GF Score
Get the complete analysis for LSE:BVXP
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:BVXP has been successfully added to your 
